Sirna Therapeutics to Present at BioJapan 2006 World Business Forum
08 Settembre 2006 - 10:00PM
PR Newswire (US)
SAN FRANCISCO, Sept. 8 /PRNewswire-FirstCall/ -- Sirna
Therapeutics, Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi
therapeutics company, announced today that Bharat M. Chowrira,
Ph.D., J.D., VP-Legal Affairs and Chief Patent Counsel, is
scheduled to participate on a panel at the BioJapan 2006 World
Business Forum in Osaka, Japan, from 1:30 to 3:30 pm on Friday,
September 15, 2006. Dr. Chowrira's presentation, "Killing the
Messenger with RNAi - Harnessing a potent endogenous mechanism for
gene silencing," will be part of the panel "Can Hepatitis C be
cured with siRNA?" He will be joined on the panel by Dr. Junichi
Yano, Member of the Board, Research and Development Division,
Nippon-Shinyaku Co., Ltd. and Dr. Takonori Yokota, Professor, Tokyo
Medical and Dental University. Dr. Yano will serve as chairman of
the panel and Dr. Takonori will serve as a speaker on the panel.
The BioJapan 2006 World Business Forum conference will feature
leading biotech companies from around the world and expects to
attract more than 20,000 visitors. For more information on this
conference, please log onto
http://expo.nikkeibp.co.jp/biojapan/2006/eng/. About Sirna
Therapeutics Sirna Therapeutics is a clinical-stage biotechnology
company developing RNAi-based therapies for serious diseases and
conditions, including age-related macular degeneration (AMD),
hepatitis C, dermatology, asthma, respiratory syncytial virus (RSV)
and Huntington's disease. Sirna Therapeutics completed its Phase 1
clinical trial for Sirna-027 in AMD in 2005 and with its strategic
partner, Allergan, Inc., will move Sirna-027 into Phase 2 clinical
trials in the second half of 2006. Sirna has selected a clinical
candidate for hepatitis C virus, Sirna-034, which the Company plans
to bring into Phase 1 clinical trials by the end of 2006. Sirna has
established an exclusive multi-year strategic alliance with
GlaxoSmithKline for the development of siRNA compounds for the
treatment of respiratory diseases. Sirna has a leading intellectual
property portfolio in RNAi covering over 250 mammalian gene and
viral targets and over 200 issued or pending patents covering other
major aspects of RNAi technology, including the microRNA
technology. More information on Sirna Therapeutics is available on
the Company's web site at http://www.sirna.com/. Safe Harbor
Statement Statements in this press release which are not strictly
historical are "forward-looking" statements which should be
considered as subject to many risks and uncertainties. For example,
most drug candidates do not become approved drugs. The development
of Sirna-027 and Sirna-034 as well as Sirna's other programs are
still at a relatively early stage. All of these programs, and
Sirna's ability to obtain milestone and royalty payments for them,
are subject to significant risks and unknowns, are highly
contingent upon future successes, and require significant funding.
In addition, patent applications may not result in issued patents,
and issued patents may not be enforceable or could be invalidated.
Other risks and uncertainties include, among others, Sirna's early
stage of development, Sirna's history and expectation of losses and
need to raise capital, Sirna's need to obtain clinical validation
and regulatory approval for Sirna-027, Sirna-034 and Sirna's other
product candidates, any of which could have negative results,
Sirna's need to engage collaborators, Sirna's need to obtain and
protect intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Stephan Herrera
Executive Director, Investor Relations Sirna Therapeutics, Inc. +1
415 512 7200 Stephanie Carrington The Ruth Group +1 646 536 7017
DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Stephan Herrera,
Executive Director, Investor Relations of Sirna Therapeutics, Inc.,
+1-415-512-7200, ; or Stephanie Carrington of The Ruth Group,
+1-646-536-7017, , for Sirna Therapeutics, Inc. Web site:
http://expo.nikkeibp.co.jp/biojapan/2006/eng Web site:
http://www.sirna.com/
Copyright
Grafico Azioni Sirna Therapeutics (NASDAQ:RNAI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Sirna Therapeutics (NASDAQ:RNAI)
Storico
Da Set 2023 a Set 2024